

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	10/055,109
---------------------------	------------

<b>Filing Date</b>	1/23/2002
--------------------	-----------

<b>First Named Inventor</b>	Shi et al.
-----------------------------	------------

Group Art Unit	1645
----------------	------

Examiner Name	Unknown
---------------	---------

Attorney Docket Number	TM0066-UT
------------------------	-----------

(use as many sheets as necessary)

Sheet 1 of 3

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

6/17/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/055,109		
		Filing Date	1/23/2002		
		First Named Inventor	Shi et al.		
		Group Art Unit	1645		
		Examiner Name	Unknown		
Sheet	2	of	3	Attorney Docket Number	TM0066-UT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Ac	AA	ADAMS et al., "Complementary DNA sequencing: Expressed sequence tags and human genome project." <u>Science</u> 252:1651-1656, (1991).	
	AB	DEMPSEY et al., "A cardiovascular EST repertoire: progress and promise for understanding cardiovascular disease." <u>Mol. Med. Today</u> 6:231-237, (2000).	
	AC	FISHEL et al., "The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer." <u>Cell</u> 75:1027-1038, (1993).	
	AD	GRAVES, D., "Powerful tools for genetic analysis come of age." <u>Trends Biotechnol.</u> 17:127-134, (1999).	
	AE	GUBLER et al., "A simple and very efficient method for generating cDNA libraries." <u>Gene</u> 25:263-269, (1983).	
	AF	KARP, P., "Database links are a foundation for interoperability." <u>Trends Biotechnol.</u> 14:273-279, 1996	
	AG	KOYAMA et al., "Structure of a cytotoxic T-lymphocyte-specific gene shows a strong homology to fibrinogen $\beta$ and $\gamma$ chains." <u>Proc. Natl. Acad. Sci. USA</u> 84:1609-1613, (1987).	
	AH	LEVY-LAHAD et al., "A familial Alzheimer's disease locus on chromosome 1." <u>Science</u> 269:970-977, (1995).	
	AI	PAN et al., "The receptor for the cytotoxic ligand TRAIL." <u>Science</u> 276:111-113, (1997).	
	AJ	PAPADOPOULOS et al., "Mutation of <i>mutL</i> homolog in hereditary colon cancer." <u>Science</u> 263:1625-1629, (1994).	
Ac	AK	RICHMOND et al., "Chasing the dream: plant EST microarrays." <u>Curr. Opin. Plant Biol.</u> 3:108-116, (2000).	

Examiner Signature	<i>Ann Kr. Chakrabarti</i>	Date Considered	6/19/02
--------------------	----------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/055,109
		Filing Date	1/23/2002
		First Named Inventor	Shi et al.
		Group Art Unit	1645
		Examiner Name	Unknown
		Attorney Docket Number	TM0066-UT
Sheet	3	of	3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Ae	AL	SHERIDAN et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors." <u>Science</u> 277:818-821, (1997).	
	AM	STRAUSBERG et al., "The Cancer Genome Anatomy Project: building an annotated gene index." <u>Trends Genet.</u> 16(3):103-106, (2000).	
	AN	VINCENZ et al, "Fas-associated death domain protein interleukin-1 $\beta$ -converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling." <u>J. Biol. Chem.</u> 272(10):6578-6583, (1997).	
	AO	YAMAMOTO et al., "Use of serial analysis of gene expression (SAGE) technology." <u>J. Immunol. Meth.</u> 250:45-66, (2001).	
	AP	ZIPFEL et al., "Complexity of the primary genetic response to mitogenic activation of human T cells." <u>Mol. Cell. Biol.</u> 9(3):1041-1048, (1989).	
Ae	AQ	ZWEIGER et al., "From expressed sequence tags to 'epigemonics': an understanding of disease processes." <u>Curr. Opin. Biotechnol.</u> 8:684-687, (1997).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231